Procept BioroboticsPRCT
PRCT
About: PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Employees: 756
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
119% more call options, than puts
Call options by funds: $20.2M | Put options by funds: $9.22M
29% more funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 9 (+2) [Q1 2025]
4% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 50
2% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 95
0% less funds holding
Funds holding: 278 [Q4 2024] → 277 (-1) [Q1 2025]
1.03% less ownership
Funds ownership: 93.03% [Q4 2024] → 92.0% (-1.03%) [Q1 2025]
28% less capital invested
Capital invested by funds: $4.05B [Q4 2024] → $2.94B (-$1.12B) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$70
15%
upside
Avg. target
$77
27%
upside
High target
$84
39%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Craig Bijou | 39%upside $84 | Buy Maintained | 25 Apr 2025 |
Truist Securities Richard Newitter | 15%upside $70 | Buy Maintained | 11 Apr 2025 |
Financial journalist opinion
Positive
Market Watch
4 weeks ago
19 stocks at the intersection of AI and robotics that could see big sales boosts
Industrial robots have been around for decades. They're often used on manufacturing lines, where they perform automated tasks.
Neutral
GlobeNewsWire
1 month ago
PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June
SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at four upcoming investor conferences in May and June.
Neutral
GlobeNewsWire
1 month ago
PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops
Presentations underscore long-term clinical outcomes, safety and durability in BPH treatment Attendees invited to experience hands-on HYDROS Robotic System demonstrations SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT) (“PROCEPT”), a surgical robotics company whose mission is to revolutionize BPH treatment globally, today announced an extensive lineup of scientific presentations and interactive workshops at the 2025 American Urological Association (AUA) Annual Meeting, taking place April 26–29 in Las Vegas, Nevada.
Neutral
Seeking Alpha
1 month ago
PROCEPT BioRobotics Corporation (PRCT) Q1 2025 Earnings Call Transcript
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations & Business Operations Reza Zadno - President & Chief Executive Officer Sham Shiblaq - Executive Vice President & Chief Commercial Officer Kevin Waters - Executive Vice President & Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Craig Bijou - Bank of America Securities Patrick Wood - Morgan Stanley Richard Newitter - Truist Brandon Vazquez - William Blair Josh Jennings - TD Cowen Chris Pasquale - Nephron Research Mike Kratky - Leerink Partners Nathan Treybeck - Wells Fargo Michael Sarcone - Jefferies Ryan Zimmerman - BTIG Operator Good morning and welcome to PROCEPT BioRobotics First Quarter 2025 Earnings Conference Call. At this time, all participants are in listen-only mode.
Negative
Zacks Investment Research
1 month ago
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.51 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2025.
Neutral
GlobeNewsWire
2 months ago
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas
SAN JOSE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company, whose mission is to revolutionize BPH treatment globally, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Aria Resort in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. Guests are encouraged to register in advance by clicking HERE. Registration is recommended to secure your spot.
Neutral
GlobeNewsWire
2 months ago
WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation
Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a randomized, multicenter trial Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a randomized, multicenter trial
Neutral
GlobeNewsWire
3 months ago
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada
SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Venetian Hotel in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time.
Positive
Seeking Alpha
3 months ago
Procept BioRobotics: Strong Growth, But Profitability Seems Far Away
PROCEPT BioRobotics shows strong revenue growth and expanding market presence but struggles with profitability and rising operational costs. The company's HYDROS robotic system and consumables business are driving revenue, with significant expansion in the U.S. and promising international growth. The FDA's clearance for Aquablation therapy in prostate cancer patients presents a long-term opportunity, though profitability remains a distant goal.
Charts implemented using Lightweight Charts™